Ovarian Screening Study
|ClinicalTrials.gov Identifier: NCT00267072|
Recruitment Status : Completed
First Posted : December 20, 2005
Last Update Posted : January 9, 2018
The objectives of this study are:
- To identify women at increased risk for developing ovarian cancer
- To detect ovarian cancers at an early stage
- To investigate the role of tumor membrane fragments as tumor markers for early ovarian carcinoma
|Condition or disease|
In the year 2001 approximately 23,400 women in the USA are expected to be diagnosed with ovarian carcinoma and 13,900 will die of the disease. This means that within the USA more women die annually from ovarian cancer than all other gynecologic malignancies combined. Within the Commonwealth of Kentucky approximately 250 women per year develop ovarian carcinoma.
Survival for patients with ovarian cancer is directly related to the stage of disease at diagnosis. Unfortunately, the majority of women present with advanced disease (Stage III and IV) and most of these patients will die of the disease.
The aim of screening for ovarian cancer is to reduce the morbidity and mortality by detecting the disease at an early stage since ovarian cancer detected when disease is confined to the ovary (Stage I) is associated with a dramatically improved 5-year survival. Disease confined to the ovary may be cured in over 90% of patients, in some cases without the need for chemotherapy.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||The University of Louisville Ovarian Screening Study|
|Study Start Date :||June 2001|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00267072
|United States, Kentucky|
|James Graham Brown Cancer Center|
|Louisville, Kentucky, United States, 40202|
|Principal Investigator:||Cyril W. Helm, MD||University of Louisville, James Graham Brown Cancer Center|